Galunisertib Plus Gemcitabine vs. Gemcitabine for First-Line Treatment of Patients With Unresectable Pancreatic Cancer
British Journal of Cancer - United Kingdom
doi 10.1038/s41416-018-0246-z
Full Text
Open PDFAbstract
Available in full text
Date
October 15, 2018
Authors
Publisher
Springer Science and Business Media LLC